Ivabradine for treatment of heart failure

References

• Bocchi EA, Braga FG, Ferreira SM, et al. Sociedade Brasileira de Cardiologia. [III Brazilian guidelines on chronic heart failure]. Arq Bras Cardiol. 2009;93(1 Suppl 1):3–70.
   PubMedGoogle Scholar
• Farré N, Vela E, Clèries M, et al. Real world heart failure epidemiology and outcome: a population-based analysis of 88,195 patients. PLoS One. 2017;12:e0172745.
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Virani SS, Callaway CW, et al. American Heart Association Council on epidemiology and prevention statistics committee and stroke statistics subcommittee. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation. 2018;137:e67–e492.
   PubMed Web of Science ®Google Scholar
• Kannel WB, Kannel C, Paffenbarger RS Jr, et al. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J. 1987;113:1489–1494.
   PubMed Web of Science ®Google Scholar
• Palatini P, Benetos A, Julius S. Impact of increased heart rate on clinical outcomes in hypertension: implications for antihypertensive drug therapy. Drugs. 2006;66:133–144.
   PubMed Web of Science ®Google Scholar
• Jouven X, Empana JP, Schwartz PJ, et al. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med. 2005;352:1951–1958.
   PubMed Web of Science ®Google Scholar
• Diaz A, Bourassa MG, Guertin MC, et al. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J. 2005;26:967–974.
   PubMed Web of Science ®Google Scholar
• Fox K, Ford I, Steg PG, et al. BEAUTIFUL investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet. 2008;372:817–821.
   PubMed Web of Science ®Google Scholar
• Lechat P, Hulot JS, Escolano S, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II trial. Circulation. 2001;103:1428–1433.
   PubMed Web of Science ®Google Scholar
• Böhm M, Swedberg K, Komajda M, et al. “SHIFT Investigators. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomized placebo-controlled trial.” Lancet. 2010;376:886–894.
   PubMed Web of Science ®Google Scholar
• Mulieri LA, Hasenfuss G, Leavitt B, et al. Altered myocardial force-frequency relation in human heart failure. Circulation. 1992;85:1743–1750.
   PubMed Web of Science ®Google Scholar
• Böhm M, Borer J, Ford I, et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol. 2013;102:11–22.
   PubMed Web of Science ®Google Scholar
• McAlister FA, Wiebe N, Ezekowitz JA, et al. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med. 2009;150:784–794.
   PubMed Web of Science ®Google Scholar
• Ziff OJ, Lane DA, Samra M, et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ. 2015;351:h4451.
   PubMed Web of Science ®Google Scholar
• Ambrosy AP, Butler J, Ahmed A, et al. The use of digoxin in patients with worsening chronic heart failure: reconsidering an old drug to reduce hospital admissions. J Am Coll Cardiol. 2014;63:1823–1832.
   PubMed Web of Science ®Google Scholar
• Nul DR, Doval HC, Grancelli HO, et al. Heart rate is a marker of amiodarone mortality reduction in severe heart failure. The GESICA-GEMA investigators. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina-Grupo de Estudios Multicéntricos en Argentina. J Am Coll Cardiol. 1997;29:1199–1205.
   PubMedGoogle Scholar
• Massie BM, Fisher SG, Radford M, et al. Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. CHF-STAT Investigators. Circulation. 1996;93:2128–2134.
   PubMed Web of Science ®Google Scholar
• Santangeli P, Rame JE, Birati EY, et al. Management of ventricular arrhythmias in patients with advanced heart failure. J Am Coll Cardiol. 2017;69:1842–1860.
   PubMed Web of Science ®Google Scholar
• Santangeli P, Muser D, Maeda S, et al. Comparative effectiveness of antiarrhythmic drugs and catheter ablation for the prevention of recurrent ventricular tachycardia in patients with implantable cardioverter-defibrillators: A systematic review and meta-analysis of randomized controlled trials. Heart Rhythm. 2016;13:1552–1559.
   PubMed Web of Science ®Google Scholar
• Flannery G, Gehrig-Mills R, Billah B, et al. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol. 2008;101:865–869.
   PubMed Web of Science ®Google Scholar
• Dobre D, Borer JS, Fox K, et al. Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties. Eur J Heart Fail. 2014;16:76–85.
   PubMed Web of Science ®Google Scholar
• Swedberg K, Komajda M, Böhm M, et al. “SHIFT investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.” Lancet. 2010;376:875–885.
   PubMed Web of Science ®Google Scholar
• Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525–533.
   PubMed Web of Science ®Google Scholar
• Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349–1355.
   PubMed Web of Science ®Google Scholar
• Packer M, Coats AJ, Fowler MB, et al. Carvedilol prospective randomized cumulative survival study group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651–1658.
   PubMed Web of Science ®Google Scholar
• Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999;353:2001–2007.
   PubMed Web of Science ®Google Scholar
• Bocchi EA, Böhm M, Borer JS, et al. “SHIFT investigators. Effect of combining ivabradine and β-blockers: focus on the use of carvedilol in the SHIFT population.” Cardiology. 2015;131:218–224.
   PubMed Web of Science ®Google Scholar
• Das D, Savarese G, Dahlström U, et al. Ivabradine in heart failure: the representativeness of SHIFT (Systolic Heart Failure Treatment With the IF Inhibitor Ivabradine Trial) in a broad population of patients with chronic heart failure. Circ Heart Fail. 2017;10:9.
   Web of Science ®Google Scholar
• Elder DH, Mohan M, Cochrane L, et al. Characterizing patients with chronic heart failure in community care after hospitalization: a potential role for ivabradine. Cardiovasc Ther. 2015;30:104–108.
   Google Scholar
• Deedwania P. Selective and specific inhibition of if with ivabradine for the treatment of coronary artery disease or heart failure. Drugs. 2013;73:1569–1586.
   PubMed Web of Science ®Google Scholar
• DiFrancesco D. Pacemaker mechanisms in cardiac tissue. Annu Rev Physiol. 1993;55:455–472.
   PubMed Web of Science ®Google Scholar
• Badu-Boateng C, Jennings R, Hammersley D. The therapeutic role of ivabradine in heart failure. Ther Adv Chronic Dis. 2018;9:199–207.
   PubMed Web of Science ®Google Scholar
• Hasenfuss G, Mann DL. Pathophysiology of heart failure. In: Zipes DP, Libby P, Bonow RO, et al., editors. Braunwalds´s heart disease: a textbook of cardiovascular diseases. 11th ed. Philadelphia: Elsevier; 2018. p. 442–461.e3.
   Google Scholar
• Raymond-Paquin A, Nattel S, Wakili R, et al. Mechanisms and clinical significance of arrhythmia-induced cardiomyopathy. Can J Cardiol. 2018;34:1449–1460.
   PubMed Web of Science ®Google Scholar
• Sugumar H, Prabhu S, Voskoboinik A, et al. Arrhythmia induced cardiomyopathy. J Arrhythm. 2018;34:376–383.
   PubMed Web of Science ®Google Scholar
• Gopinathannair R, Etheridge SP, Marchlinski FE, et al. Arrhythmia-induced cardiomyopathies: mechanisms, recognition, and management. J Am Coll Cardiol. 2015;66:1714–1728.
   PubMed Web of Science ®Google Scholar
• Mueller KAL, Heinzmann D, Klingel K, et al. Histopathological and immunological characteristics of tachycardia-induced cardiomyopathy. J Am Coll Cardiol. 2017;69:2160–2172.
   PubMed Web of Science ®Google Scholar
• Ragueneau I, Laveille C, Jochemsen R, et al. Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. Clin Pharmacol Ther. 1998;64:192–203.
   PubMed Web of Science ®Google Scholar
• Oliva F, Sormani P, Contri R, et al. Heart rate as a prognostic marker and therapeutic target in acute and chronic heart failure. Int J Cardiol. 2018;253:97–104.
   PubMed Web of Science ®Google Scholar
• Bui AL, Grau-Sepulveda MV, Hernandez AF, et al. Admission heart rate and in-hospital outcomes in patients hospitalized for heart failure in sinus rhythm and in atrial fibrillation. Am Heart J. 2013;165:567–574.e6.
   PubMed Web of Science ®Google Scholar
• Heusch G. Heart rate and heart failure. Not a simple relationship. Circ J. 2011;75(2):229–236.
   PubMed Web of Science ®Google Scholar
• Rønning L, Bakkehaug JP, Rødland L, et al. Opposite diastolic effects of omecamtiv mecarbil versus dobutamine and ivabradine co-treatment in pigs with acute ischemic heart failure. Physiol Rep. 2018;6:e13879.
   PubMed Web of Science ®Google Scholar
• Lofrano-Alves MS, Issa VS, Biselli B, et al. “Control of sinus tachycardia as an additional therapy in patients with decompensated heart failure (CONSTATHE-DHF): A randomized, double-blind, placebo-controlled trial.” J Heart Lung Transplant. 2016;35:1260–1264.
   PubMed Web of Science ®Google Scholar
• Nguyen LS, Squara P, Amour J, et al. Intravenous ivabradine versus placebo in patients with low cardiac output syndrome treated by dobutamine after elective coronary artery bypass surgery: a phase 2 exploratory randomized controlled trial. Crit Care. 2018;22:193.
   PubMed Web of Science ®Google Scholar
• Hidalgo FJ, Anguita M, Castillo JC, et al. Effect of early treatment with ivabradine combined with beta-blockers versus beta-blockers alone in patients hospitalised with heart failure and reduced left ventricular ejection fraction (ETHIC-AHF): A randomised study. Int J Cardiol. 2016;217:7–11.
   PubMed Web of Science ®Google Scholar
• Hidalgo F, Carrasco F, Castillo JC, et al. Effect of early treatment with ivabradine plus beta-blockers on long-term outcomes in patients hospitalized with systolic heart failure. Rev Esp Cardiol. 2018;71:1086–1088.
   PubMed Web of Science ®Google Scholar
• Volterrani M, Cice G, Caminiti G, et al. Effect of carvedilol, ivabradine or their combination on exercise capacity in patients with heart failure (the CARVIVA HF trial). Int J Cardiol. 2011;151:218–224.
   PubMed Web of Science ®Google Scholar
• Bagriy AE, Schukina EV, Samoilova OV, et al. Addition of ivabradine to β-blocker improves exercise capacity in systolic heart failure patients in a prospective, open-label study. Adv Ther. 2015;32:108–119.
   PubMed Web of Science ®Google Scholar
• Sarullo FM, Fazio G, Puccio D, et al. Impact of “off-label“ use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure. J Cardiovasc Pharmacol Ther. 2010;15:349–355.
   PubMed Web of Science ®Google Scholar
• Anantha Narayanan M, Reddy YN, Baskaran J, et al. Ivabradine in the treatment of systolic heart failure - A systematic review and meta-analysis. World J Cardiol. 2017;9:182–190.
   PubMed Web of Science ®Google Scholar
• Komajda M, Böhm M, Borer JS, et al. Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis. Eur J Heart Fail. 2018;20:1315–1322.
   PubMed Web of Science ®Google Scholar
• Koruth JS, Lala A, Pinney S, et al. The clinical use of ivabradine. J Am Coll Cardiol. 2017;70:1777–1784.
   PubMed Web of Science ®Google Scholar
• Bocchi EA, Bestetti RB, Scanavacca MI, et al. Chronic Chagas heart disease management: from etiology to cardiomyopathy treatment. J Am Coll Cardiol. 2017;70:1510–1524.
   PubMed Web of Science ®Google Scholar
• Bocchi EA, Rassi S, Guimarães GV. Argentina, Chile, and Brazil SHIFT Investigators. Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial. ESC Heart Fail. 2018;5:249–256.
   PubMedGoogle Scholar
• Haghikia A, Tongers J, Berliner D, et al. Early ivabradine treatment in patients with acute peripartum cardiomyopathy: subanalysis of the German PPCM registry. Int J Cardiol. 2016;216:165–167.
   PubMed Web of Science ®Google Scholar
• Komajda M, Isnard R, Cohen-Solal A, et al. prEserveD left ventricular ejectIon fraction chronic heart Failure with ivabradine studY (EDIFY) Investigators. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. Eur J Heart Fail. 2017;19:1495–1503.
   PubMed Web of Science ®Google Scholar
• Bonnet D, Berger F, Jokinen E, et al. Ivabradine in children with dilated cardiomyopathy and symptomatic chronic heart failure. J Am Coll Cardiol. 2017;70:1262–1272.
   PubMed Web of Science ®Google Scholar
• Mehta N, Bapat A, Tedrow U, et al. Inappropriate sinus tachycardia in a heart transplant successfully treated with ivabradine. Europace. 2017;19:1100.
   PubMed Web of Science ®Google Scholar
• Mert KU, Dural M, Mert GÖ, et al. Effects of heart rate reduction with ivabradine on the international ındex of erectile function (IIEF-5) in patients with heart failure. Aging Male. 2018;21:93–98.
   PubMed Web of Science ®Google Scholar
• Rohm I, Kretzschmar D, Pistulli R, et al. Impact of ivabradine on inflammatory markers in chronic heart failure. J Immunol Res. 2016;2016:6949320.
   PubMedGoogle Scholar
• Ordu S, Yildiz BS, Alihanoglu YI, et al. Effects of ivabradine therapy on heart failure biomarkers. Cardiol J. 2015;22:501–509.
   PubMed Web of Science ®Google Scholar
• Turley SL, Francis KE, Lowe DK, et al. Emerging role of ivabradine for rate control in atrial fibrillation. Ther Adv Cardiovasc Dis. 2016;10:348–352.
   PubMedGoogle Scholar
• Oliphant CS, Owens RE, Bolorunduro OB, et al. Ivabradine: a review of labeled and off-label uses. Am J Cardiovasc Drugs. 2016;16:337–347.
   PubMed Web of Science ®Google Scholar
• de Gregorio C, Potenza G, Ferraro G. Effectiveness of the combination therapy with lisinopril, ivabradine and multivitamin supplementation in anthracycline-induced severe cardiotoxicity. Int J Cardiol. 2014;176:1374–1376.
   PubMed Web of Science ®Google Scholar
• Fox K, Ford I, Steg PG, et al., SIGNIFY Investigators. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014;371:1091–1099.
   PubMed Web of Science ®Google Scholar
• Martin RI, Pogoryelova O, Koref MS, et al. Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials. Heart. 2014;100:1506–1510.
   PubMed Web of Science ®Google Scholar
• Lu Y, Li K, Liu XS, et al. Ivabradine and atrial fibrillation: A double-edged sword. Int J Cardiol. 2016;223:182–185.
   PubMed Web of Science ®Google Scholar
• Frommeyer G, Weller J, Ellermann C, et al. Ivabradine aggravates the proarrhythmic risk in experimental models of long QT syndrome. Cardiovasc Toxicol. 2018;19:129–135.
   PubMed Web of Science ®Google Scholar
• Hancox JC, Melgari D, Dempsey CE, et al. hERG potassium channel inhibition by ivabradine may contribute to QT prolongation and risk of torsades de pointes. Ther Adv Drug Saf. 2015;6:177–179.
   PubMed Web of Science ®Google Scholar
• Mittal SR. Slow junctional rhythm, QTc prolongation and transient torsades de-pointes following combined use of ivabradine, diltiazem and ranolazine. J Assoc Physicians India. 2014;62:426–427.
   PubMedGoogle Scholar
• Cocco G, Jerie P. Torsades de pointes induced by the concomitant use of ivabradine and azithromycin: an unexpected dangerous interaction. Cardiovasc Toxicol. 2015;15:104–106.
   PubMed Web of Science ®Google Scholar
• Mathiaux F, Dulaurent S, Julia F, et al. Case report of ivabradine intoxication. J Anal Toxicol. 2014;38:231–232.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. ESC scientific document group. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–2200.
   PubMedGoogle Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2016;68:1476–1488.
   PubMed Web of Science ®Google Scholar
• Bocchi EA, Marcondes-Braga FG, Bacal F, et al. Updating of the Brazilian guideline for chronic heart failure – 2012. Arq Bras Cardiol. 2012;98:1–33.
   PubMed Web of Science ®Google Scholar
• Adena MA, Hamann G, Sindone AP. Cost-effectiveness of ivabradine in the treatment of chronic heart failure. Heart Lung Circ. 2019;28:414–422.
   PubMed Web of Science ®Google Scholar
• Kansal AR, Cowie MR, Kielhorn A, et al. Cost-effectiveness of ivabradine for heart failure in the United States. J Am Heart Assoc. 2016;5:5.
   Web of Science ®Google Scholar
• Kansal AR, Krotneva S, Tafazzoli A, et al. Financial impact of ivabradine on reducing heart failure penalties under the hospital readmission reduction program. Curr Med Res Opin. 2017;33:185–191.
   PubMed Web of Science ®Google Scholar
• Fernandez de BJ, Gonzalez FO, Lopez de SE, et al. Cost-effectiveness analysis of ivabradine in heart failure with reduced left ventricular ejection fraction in Spain. Value Health. 2014;17:A486.
   PubMed Web of Science ®Google Scholar
• Kourlaba G, Parissis J, Karavidas A, et al. Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece. BMC Health Serv Res. 2014;14:631.
   PubMed Web of Science ®Google Scholar
• Griffiths A, Paracha N, Davies A, et al. The cost effectiveness of ivabradine in the treatment of chronic heart failure from the U.K. National Health Service perspective. Heart. 2014;100:1031–1036.
   PubMed Web of Science ®Google Scholar